Citations

Clear

69 citation(s) found for "Feagan, Brian".

Endoscopic scoring indices for assessing disease severity in familial adenomatous polyposis: Systematic review
Silverman, Anna L. , Bouchiba, Hicham , Aelvoet, Arthur S. , MacDonald, John K, Dekker, Evelien , Zayadi, Alexa, Le, Jessica, Feagan, Brian G. , Jairath, Vipul , Ma, Christopher , Samadder, Jewel, Jairath, Vipul , Jairath, Vipul , Silverman, Anna Lerman , Jairath, V , Jairath, V , Dekker, Evelien , Jairath, Vipul , Le, Jessica

Mayo Clinic

Endoscopy International Open | June 18, 2024 | Volume: 12 | Issue: 06 | Pages: E799-E809

10.1055/a-2330-8037 | PMID 38904059 Get It

Abstract Background and study aims There is limited consensus on the optimal method for measuring disease severity in familial adenomatous polyposis (FAP). We aimed to systematically review the operating properties of existing endoscopic severity indices for FAP. Methods We searched MEDLINE, EMBASE, and the Cochrane Library from inception to February 2023 to identify randomized controlled trials (RCTs) that utilized endoscopic outcomes or studies that evaluated the operating properties of endoscopic disease severity indices in FAP. Results A total of 134 studies were included. We evaluated scoring indices and component items of scoring indices, such as polyp count, polyp size, and histology. Partial validation was observed for polyp count and size. The most commonly reported scoring index was the Spigelman classification system, which was used for assessing the severity of duodenal involvement. A single study reported almost perfect interobserver and intra-observer agreement for this system. The InSIGHT polyposis staging system, which was used for assessing colorectal polyp burden, has been partially validated. It showed substantial interobserver reliability; however, the intra-observer reliability was not assessed. Novel criteria for high-risk gastric polyps have been developed and assessed for interobserver reliability. However, these criteria showed a poor level of agreement. Other scoring indices assessing the anal transition zone, duodenal, and colorectal polyps have not undergone validation. Conclusions There are no fully validated endoscopic disease severity indices for FAP. Development and validation of a reliable and responsive endoscopic disease severity instrument will be informative for clinical care and RCTs of pharmacological therapies for FAP.
Diagnosis of Inflammatory Bowel Disease–Associated Peripheral Arthritis: A Systematic Review
Falloon, Katherine , Dossaji, Zahra, Mude, Pooja , Abushamma, Suha , Bhalla, Jaideep , Bhattacharya, Abhik , Cheemalavagu, Shashank , Colombel, J.F., Ha, Christina , Horst, Sara , Hou, Jason K. , Husni, M. Elaine , Kline, Theresa , Long, Millie D. , Patel, Aditi, Scherl, Ellen , Qazi, Taha , Cohen, Benjamin L, Feagan, Brian G. , Rieder, Florian , Ha, Christina , Herfarth, Hans H , Sleiman, Joseph , Qazi, Taha , Ananthakrishnan, Ashwin N. , Barnes, Edward L. , Cross, Raymond K. , Ermann, Joerg , Herfarth, Hans , Kuhn, Kristine A. , Loftus, Edward V. , Lukin, Dana J. , Rubin, David T. , Shah, Shiraz Ali , Siaton, Bernadette C. , Sleiman, Joseph , Weisman, Michael H. , Cohen, Benjamin L

Mayo Clinic

Inflammatory Bowel Diseases | June 5, 2024 | Volume: 31 | Issue: 3 | Pages: 812-842

10.1093/ibd/izae114 | PMID 38836521 Get It

Abstract Background Inflammatory bowel disease (IBD)–associated peripheral spondyloarthritis (pSpA) decreases quality of life and remains poorly understood. Given the prevalence of this condition and its negative impact, it is surprising that evidence-based disease definitions and diagnostic strategies are lacking. This systematic review summarizes available data to facilitate development and validation of diagnostics, patient-reported outcomes, and imaging indices specific to this condition. Methods A literature search was conducted. Consensus or classification criteria, case series, cross-sectional studies, cohort studies, and randomized controlled trials related to diagnosis were included. Results A total of 44 studies reporting data on approximately 1500 patients with pSpA were eligible for analysis. Data quality across studies was only graded as fair to good. Due to large heterogeneity, meta-analysis was not possible. The majority of studies incorporated patient-reported outcomes and a physical examination. A total of 13 studies proposed or validated screening tools, consensus, classification, or consensus criteria. A total of 28 studies assessed the role of laboratory tests, none of which were considered sufficiently accurate for use in diagnosis. A total of 17 studies assessed the role of imaging, with the available literature insufficient to fully endorse any imaging modality as a robust diagnostic tool. Conclusions This review highlights existing inconsistency and lack of a clear diagnostic approach for IBD-associated pSpA. Given the absence of an evidence-based approach, a combination of existing criteria and physician assessment should be utilized. To address this issue comprehensively, our future efforts will be directed toward pursuit of a multidisciplinary approach aimed at standardizing evaluation and diagnosis of IBD-associated pSpA.
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn’s Disease
Khanna, Reena , Feagan, Brian G. , Stitt, Larry, McDonald, John WD, Bressler, Brian , Panaccione, Remo , Shackelton, Lisa M. , VanViegen, Tanja, Jairath, Vipul , D’Haens, Geert , Sandborn, William J. , Jairath, Vipul , Jairath, Vipul , Panaccione, Remo , D'Haens, G , Jairath, V , Jairath, V , Jairath, Vipul , Zou, Guangyong , Loftus, Edward V. , Daperno, Marco

Mayo Clinic

Inflammatory Bowel Diseases | April 25, 2024 | Volume: 31 | Issue: 3 | Pages: 706-715

10.1093/ibd/izae089 | PMID 38661492 Get It

Abstract Background Regulatory guidance for Crohn’s disease trials recommends coprimary efficacy end points that evaluate both symptoms and mucosal inflammation. We aimed to characterize the operating properties of commonly used disease activity assessments alone and in combination. Methods Endoscopic and clinical data were available for 129 participants from the Study of Biologic and Immunomodulator Naïve Patients in Crohn’s Disease trial. Readers scored the Simple Endoscopic Score for Crohn’s Disease and the Crohn’s Disease Endoscopic Index of Severity using standardized conventions. Index reliability was determined using intraclass correlation coefficients. Index responsiveness was assessed using standardized effect sizes based upon treatment assignment. Outcomes were evaluated for optimal sensitivity to treatment effect. Results Substantial inter-rater reliability was observed when the Simple Endoscopic Score for Crohn’s Disease and Crohn’s Disease Endoscopic Index of Severity were used as continuous measures (intraclass correlation coefficient, 0.64; 95% confidence interval [CI], 0.50-0.73; and 0.62 95% CI, 0.36-0.77) compared with moderate reliability when dichotomized (0.46; 95% CI, 0.26-0.65; and 0.51; 95% CI, 0.00-0.78). The Simple Endoscopic Score for Crohn’s Disease, Crohn’s Disease Endoscopic Index of Severity, patient-reported outcome-2, and Crohn’s Disease Activity Index were similarly responsive (standardized effect size, 0.43, 95% CI, 0.05-0.81; 0.38, 95% CI, 0.0-0.76; 0.53, 95% CI, 0.15-0.91). A composite outcome of Crohn’s Disease Activity Index score <150 and Crohn’s Disease Endoscopic Index of Severity score <6 was most sensitive to treatment effect (28.9%; 95% CI, 11.0%-46.8%; P = .003). Conclusion Endoscopic indices were more reliable as continuous measures. Composite outcomes including endoscopy improved sensitivity to treatment effect.
Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound
Lu, Cathy , Rosentreter, Ryan E., Delisle, Maxime , White, Mattie, Parker, Claire E. , Premji, Zahra , Baker, Mark E. , Bhatnagar, Gauraang , Begun, Jakob , Bruining, David H. , Bryant, Robert V. , Christensen, Britt , Feagan, Brian G. , Jairath, Vipul , Knudsen, John M. , Kucharzik, Torsten , Maaser, Christian , Novak, Kerri L. , Taylor, Stuart A. , Wilkens, Rune , Rieder, Florian , Jairath, Vipul , Jairath, Vipul , Begun, Jakob , Bryant, Robert, Christensen, Britt , Jairath, V , Knudsen, John, Maconi, Giovanni , Novak, Kerri , Wilkens, Rune , Rieder, Florian , Lu, Cathy , Jairath, V , Jairath, Vipul , Wilson, Stephanie R. , Fletcher, Joel G. , Rimola, Jordi

Mayo Clinic

Alimentary Pharmacology & Therapeutics | March 4, 2024 | Volume: 59 | Issue: 8 | Pages: 928-940

10.1111/apt.17918 | PMID 38436124 Get It

Summary Background Stricturing Crohn's disease (CD) occurs most commonly in the terminal ileum and poses a clinical problem. Cross‐sectional imaging modalities such as intestinal ultrasound (IUS), computed tomography enterography (CTE), and magnetic resonance enterography (MRE) allow for assessment of the entire bowel wall and associated peri‐enteric findings. Radiologic definitions of strictures have been developed for CTE and MRE; their reliability and responsiveness are being evaluated in index development programs. A comprehensive assessment strategy for strictures using IUS is needed. Aims To provide a detailed summary of definitions, diagnosis and monitoring of strictures on IUS as well as technical aspects of image acquisition. Methods We searched four databases up to 6 January 2024. Two‐stage screening was done in duplicate. We assessed risk of bias using QUADAS‐2. Results There were 56 studies eligible for inclusion. Definitions for strictures on IUS are heterogeneous, but the overall accuracy for diagnosis of strictures is high. The capability of IUS for characterising inflammation versus fibrosis in strictures is not accurate enough to be used in clinical practice or trials. We summarise definitions for improvement of strictures on IUS, and discuss parameters for image acquisition and standardisation. Conclusions This systematic review is the first step for a structured program to develop a stricture IUS index for CD.
Identification of immune cell markers associated with ulcerative colitis histological disease activity in colonic biopsies
Lefèvre, Pavine, Wang, Zhongya , Teft, Wendy A., Viegen, Tanja van, Linggi, Bryan, Jairath, Vipul , Feagan, Brian G. , Pai, Rish K. , Jairath, Vipul , Jairath, Vipul , Jairath, V , Jairath, V , Jairath, Vipul , Zou, Guangyong , Casteele, Niels Vande

Mayo Clinic

Journal of Clinical Pathology | February 28, 2024 | Volume: 78 | Issue: 9 | Pages: 605-613

10.1136/jcp-2023-209327 | PMID 38418201 Get It

Aims Accurate determination of histological activity in ulcerative colitis (UC) is essential given its diagnostic and prognostic importance. Data on the relationship between histology and immune cell markers are limited. We aimed to evaluate the association between histological disease activity and immune cell marker concentration in colonic biopsies from patients with UC. Methods Sigmoid colon biopsies from 20 patients with UC were retrospectively assessed using the Robarts Histopathology Index (RHI). Targeted mass spectrometry determined the concentration of 18 immune cell markers (cluster of differentiation (CD) 4, CD8, CD19, CD20, CD40, CD56, CD68, CD103, forkhead box p3 (FOXP3), human leucocyte antigen, DR alpha chain (HLA-DRA), interleukin 10 (IL-10), IL-23 subunit alpha (IL-23A), IL-23 receptor (IL-23R), IL-2 receptor alpha chain (IL-2RA), Ki67, lymphocyte-activation gene 3 (LAG-3), programmed cell death protein 1 (PD-1) and PD ligand 1 (PD-L1)). The association between RHI score and immune cell marker concentration was quantified using Spearman’s rank correlation coefficient (ρ) and related 95% CIs. Results Fourteen of the 18 immune cell marker proteins were detected, with tissue concentration ranging from 0.003 to 11.53 fmol/µg. The overall RHI score was positively correlated with CD19, CD20, CD40, FOXP3, LAG-3, PD-1 and PD-L1 concentration (ρ=0.596–0.799) and negatively correlated with CD56 concentration (ρ=−0.460). There was no significant association between RHI score and CD4, CD8, CD68, CD103, HLA-DRA or Ki67 concentration. Conclusions This study provides insight into the correlation between immune cell marker expression and histological disease activity and the possible molecular and immunological determinants underlying microscopic disease activity in UC.
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis
Feagan, Brian G. , Ott, Elyssa , Gasink, Christopher , Godwin, Bridget, Marano, Colleen , Ye, Miao , Loftus, Edward V. , Sandborn, William J. , Loftus, Edward V , Danese, Silvio , Ghosh, Subrata , Ma, Tony Xuyen , Danese, Silvio , Abreu, María T. , Sands, Bruce E

Mayo Clinic

Journal of Crohn's and Colitis | February 2, 2024 | Volume: 18 | Issue: 7 | Pages: 1091-1101

10.1093/ecco-jcc/jjae013 | PMID 38310565 Get It

Abstract Background and Aims Previously published long-term safety data reported a favourable ustekinumab safety profile for the treatment of inflammatory bowel disease [IBD]. We present the final cumulative safety data from pooled ustekinumab IBD phase 2/3 clinical studies through 5 years in Crohn’s disease [CD] and 4 years in ulcerative colitis [UC]. Methods In phase 3 studies, patients received a single intravenous placebo or ustekinumab [130 mg or ~6 mg/kg] induction dose followed by subcutaneous maintenance doses of placebo or ustekinumab [90 mg q8w or q12w]. Analyses included all patients who received one dose of study treatment and included patients who were biologic-naïve and patients with a history of biologic failure. Safety outcomes are summarized and presented using number of events per 100 patient-years of follow-up and corresponding 95% confidence intervals. Results In this final pooled safety analysis, 2575 patients were treated with ustekinumab with 4826 patient-years of follow-up. Rates of key safety events, including major adverse cardiac events and malignancies, were similar between placebo and ustekinumab or not higher for ustekinumab. Opportunistic infections, including tuberculosis, and malignancies were reported infrequently. Rates of key safety events in the IBD group were no higher in the ustekinumab group than in the placebo group for both patients who were biologic-naïve or who had a history of biologic failure. No lymphomas or cases of posterior reversible encephalopathy syndrome [formerly known as reversible posterior leukoencephalopathy syndrome] were reported. Conclusion The final cumulative ustekinumab safety data through 5 years in CD and 4 years in UC demonstrated favourable safety compared to placebo and continue to support the well-established safety profile across all approved indications. Clinical trials.gov numbers NCT00265122, NCT00771667, NCT01369329, NCT01369342, NCT01369355, NCT02407236
Ein globaler Consensus zu Definitionen, Diagnostik und Behandlungsmanagement des fibrostenotischen Morbus Crohn des terminalen Ileums
Baker, Mark E. , Bemelman, Willem A. , D’Haens, Geert , D’Hoore, A., Feakins, Roger , Fleshner, Phillip , Ha, Christina , Lyu, R., Mao, Ren , Sandborn, William J. , Ng, S, Silverberg, Mark S. , Bruining, David H. , Feagan, Brian G. , Bettenworth, Dominik , Fletcher, Joel G. , Jairath, Vipul , Lu, Cathy , Dignass, Axel , Dotan, Iris , Henderson, G., Panés, Julián , Rogler, Gerhard , Rimola, Jordi , Siegmund, Britta , Taylor, Stuart A. , Verstockt, Bram , Gordon, Ilyssa O. , Rieder, F.

Mayo Clinic

Zeitschrift für Gastroenterologie | October 26, 2023 | Volume: 61 | Issue: 08 | Pages: e421-e422

10.1055/s-0043-1771750 Get It

S222 Endoscopic Scoring Indices for Assessing Disease Severity in Familial Adenomatous
Silverman, Anna L. , Bouchiba, Hicham , MacDonald, John K, Feagan, Brian G. , Samadder, N. Jewel , Aelvoet, Arthur S. , Jairath, Vipul , Ma, Christopher , Dekker, Evelien

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S167-S167

10.14309/01.ajg.0000950528.16770.f9 Get It

Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study
Battat, Robert , Pai, Rish K. , Wang, Zhongya , Zou, Guangyong , McDonald, John WD, Duijvestein, Marjolijn , Jeyarajah, Jenny , Parker, Claire E. , Viegen, Tanja van, Nelson, Sigrid, Boland, Brigid S. , Singh, Siddharth , Dulai, Parambir S. , Feagan, Brian G. , Sandborn, William J. , Pai, R K , Jeyarajah, Jenny , Parker, Claire E , Singh, S , Dulai, Parambir S , Feagan, B G , Jairath, V , Sandborn, W J , Zou, Guangyong , Casteele, Niels Vande , Valasek, Mark A. , Jairath, Vipul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 4, 2023 | Volume: 52 | Issue: 10 | Pages: 1574-1582

10.1111/apt.16083 | PMID 32981088 Get It

SummaryBackgroundThe optimal ulcerative colitis biopsy protocol is unclear.AimTo evaluate the number of biopsies required to accurately assess microscopic disease activity in ulcerative colitisMethodsBiopsies from patients with ≥4 rectosigmoid samples, and clinical and endoscopic data, were retrospectively obtained from a prospective biobank. Histology and endoscopic videos were read blindly. A 4‐biopsy Robarts Histopathology Index (RHI) reference score, consisting of the worst item‐level ratings from four biopsies, was compared to 1‐, 2‐ and 3‐biopsy estimates. Agreement was determined using bivariate errors‐in‐variable regression analysis (acceptance interval: ±8.25). Endoscopic activity and disease location subgroup analyses were also performed.ResultsForty‐six patients had ≥4 rectosigmoid biopsies available (N = 287). The 2‐biopsy (tolerance interval: −7.66, 4.79) and 3‐biopsy (tolerance interval: −4.86, 3.46) RHI scores demonstrated acceptable agreement with 4‐biopsy scores. One‐biopsy scores demonstrated unacceptable agreement (tolerance interval: −13.99, 7.78). Mean RHI scores using the 2‐, 3‐ and 4‐biopsy approaches were similar (6.1 ± 9.6 P = 0.36; 6.8 ± 10.5, P = 0.7; 7.5 ± 11.2), whereas the 1‐biopsy estimate was lower (4.4 ± 8.1, P = 0.06). Histological remission rates were identical for the 2‐, 3‐ and 4‐biopsy methods (65.2%, P = 1.0). Subgroup analysis demonstrated that three biopsies were required in patients with endoscopically active disease. Sampling additional colonic locations yielded lower histological remission rates compared to rectosigmoid sampling alone (33.3% vs 61.9%, P = 0.1).ConclusionsA minimum of two — conservatively, three — biopsies are required to reliably assess disease activity in a single colonic segment using the RHI. Further studies are needed of endoscopically active patients and sampling locations. These results have implications for biopsy strategies in clinical trials and practice.